UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Synthesis and regioselective alkylation of 1,6- and 1,7-naphthyridines

Tetrahedron letters, 2000-10, Vol.41 (42), p.8053-8057

2000

Volltextzugriff (PDF)

A highly potent, orally active imidazo-[4,5-b]pyridine biphenylacylsulfonamide (MK-996;L-159,282) : a new AT1-selective angiotensin II receptor antagonist

Journal of medicinal chemistry, 1994-11, Vol.37 (24), p.4068-4072

1994

Volltextzugriff (PDF)

Triazolinone Biphenylsulfonamide Derivatives as Orally Active Angiotensin II Antagonists with Potent AT1 Receptor Affinity and Enhanced AT2 Affinity

Journal of medicinal chemistry, 1994-08, Vol.37 (17), p.2808-2824

1994

Volltextzugriff (PDF)

Pharmacology of L-744,453, a novel nonpeptidyl endothelin antagonist

Life sciences (1973), 1996-03, Vol.58 (14), p.1149-1157

1996

Volltextzugriff (PDF)

Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective β3 adrenergic receptor agonist antiobesity agents

Bioorganic & medicinal chemistry letters, 2000-07, Vol.10 (13), p.1431-1434

2000

Volltextzugriff (PDF)

Triazolinones as nonpeptide angiotensin II antagonists. 2. discovery of a potent and orally active triazolinone acylsulfonamide

Bioorganic & medicinal chemistry letters, 1994-01, Vol.4 (1), p.115-120

1994

Volltextzugriff (PDF)

Human β3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamides

Bioorganic & medicinal chemistry letters, 1999-03, Vol.9 (5), p.755-758

1999

Volltextzugriff (PDF)

In vitro pharmacology of MK-996, a new potent and selective angiotensin II (AT1) receptor antagonist

Drug development research, 1994-07, Vol.32 (3), p.161-171

1994

Volltextzugriff (PDF)

3-pyridylethanolamines : Potent and selective human β3 adrenergic receptor agonists

Bioorganic & medicinal chemistry letters, 1998-11, Vol.8 (21), p.3087-3092

1998

Volltextzugriff (PDF)

Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents

Bioorganic & medicinal chemistry letters, 2000-07, Vol.10 (13), p.1431-1434

2000

Volltextzugriff (PDF)

Human β3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides

Bioorganic & medicinal chemistry letters, 1999-03, Vol.9 (5), p.749-754

1999

Volltextzugriff (PDF)

3-pyridylethanolamines: Potent and selective human β 3 adrenergic receptor agonists

Bioorganic & medicinal chemistry letters, 1998-11, Vol.8 (21), p.3087-3092

1998

Volltextzugriff (PDF)

Human beta3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides

Bioorganic & medicinal chemistry letters, 1999-03, Vol.9 (5), p.749-754

1999

Volltextzugriff (PDF)

Human beta3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamides

Bioorganic & medicinal chemistry letters, 1999-03, Vol.9 (5), p.755-758

1999

Volltextzugriff (PDF)

Development of [11C]L-159,884: a radiolabelled, nonpeptide angiotensin II antagonist that is useful for angiotensin II, AT1 receptor imaging

Applied radiation and isotopes, 1996-02, Vol.47 (2), p.211-218

1996

Volltextzugriff (PDF)

In vivo pharmacology of a novel AT1 selective angiotensin II receptor antagonist, MK-996

American journal of hypertension, 1995-01, Vol.8 (1), p.58-66

1995

Volltextzugriff (PDF)

Carbon-11 labeling of a potent, nonpeptide, at1-selective angiotensin-II receptor antagonist: MK-996

Journal of labelled compounds & radiopharmaceuticals, 1995-08, Vol.36 (8), p.729-737

1995

Volltextzugriff (PDF)

Novel aspects of the chemistry of thioamides

Naylor, E M

1988

Volltextzugriff (PDF)

In vivo pharmacology of a novel AT selective angiotensin II receptor antagonist, MK-996

American journal of hypertension, 1995-01, Vol.8 (1), p.58-66

1995

Volltextzugriff (PDF)

Triazolinones as nonpeptide angiotensin II antagonists. II : Discovery of a potent and orally active triazoline acylsulfonamide

Bioorganic & medicinal chemistry letters, 1994, Vol.4 (1), p.115-120

1994

Volltextzugriff (PDF)

Potent imidazole angiotensin II antagonists: acyl sulfonamides and acyl sulfamines as tetrazole replacements

Bioorganic & medicinal chemistry letters, 1994, Vol.4 (1), p.69-74

1994

Volltextzugriff (PDF)

Regaining your competitive edge

Long range planning, 1985-02, Vol.18 (1), p.30-35

Naylor, Michael E.

1985

Volltextzugriff (PDF)

Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study

Osteoporosis international, 2016-01, Vol.27 (1), p.21-31

2016

Volltextzugriff (PDF)

Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis

Osteoporosis international, 2019-04, Vol.30 (4), p.917-922

2019

Volltextzugriff (PDF)

International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates

Osteoporosis international, 2017-03, Vol.28 (3), p.767-774

2017

Volltextzugriff (PDF)

1 – 25 von 1.438

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.319)
Mit Volltextzugriff
(1.196)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Synthesis and regioselective alkylation of 1,6- and 1,7-naphthyridines

A highly potent, orally active imidazo-[4,5-b]pyridine biphenylacylsulfonamide (MK-996;L-159,282) : a new AT1-selective angiotensin II receptor antagonist

Triazolinone Biphenylsulfonamide Derivatives as Orally Active Angiotensin II Antagonists with Potent AT1 Receptor Affinity and Enhanced AT2 Affinity

Pharmacology of L-744,453, a novel nonpeptidyl endothelin antagonist

Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective β3 adrenergic receptor agonist antiobesity agents

Triazolinones as nonpeptide angiotensin II antagonists. 2. discovery of a potent and orally active triazolinone acylsulfonamide

Human β3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamides

In vitro pharmacology of MK-996, a new potent and selective angiotensin II (AT1) receptor antagonist

3-pyridylethanolamines : Potent and selective human β3 adrenergic receptor agonists

Synthesis and SAR of benzyl and phenoxymethylene oxadiazole benzenesulfonamides as selective beta3 adrenergic receptor agonist antiobesity agents

Human β3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides

3-pyridylethanolamines: Potent and selective human β 3 adrenergic receptor agonists

Human beta3 adrenergic receptor agonists containing cyclic ureidobenzenesulfonamides

Human beta3 adrenergic receptor agonists containing imidazolidinone and imidazolone benzenesulfonamides

Development of [11C]L-159,884: a radiolabelled, nonpeptide angiotensin II antagonist that is useful for angiotensin II, AT1 receptor imaging

In vivo pharmacology of a novel AT1 selective angiotensin II receptor antagonist, MK-996

Carbon-11 labeling of a potent, nonpeptide, at1-selective angiotensin-II receptor antagonist: MK-996

Novel aspects of the chemistry of thioamides

In vivo pharmacology of a novel AT selective angiotensin II receptor antagonist, MK-996

Triazolinones as nonpeptide angiotensin II antagonists. II : Discovery of a potent and orally active triazoline acylsulfonamide

Potent imidazole angiotensin II antagonists: acyl sulfonamides and acyl sulfamines as tetrazole replacements

Regaining your competitive edge

Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study

Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis

International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates

Suchergebnisse filtern